QuickSearch:   Number of matching entries: 0.

Search Settings

    AuthorTitleYearCompany (Country)ReftypeComments
    Eisenkrätzer, D. Implementation of new bioreactor & information technology into existing facilities 2010 Roche Diagnostics GmbH (Germany)  standard  
    Abstract:

    With the increasing number of new biological entities to be developed, Roches R&D plants face several major challenges:

    1.The development must be place cost-efficient.

    2.Short development times enable the early start of clinical studies.

    3.High flexibility is required regarding the capacity and type of the processes.

    4.The transfer from R&D plants into production facilities must run fast and smoothly.

    The requirements mentioned above lead to the development of a concept for our pilot plants that illustrates an alternative to the highly automated hard piped stainless steel plants we built before. In order to expand our capacities for process development and to implement the new concepts for plant operation, an investment project of 172 million € was approved in January 2008 by Roche’s Cooperate Executive Committee. This concept of the pilot plants is based on a process platform of Single Use Equipment working together with classic steel & glass equipment in different modular plants. To ensure fast and efficient process development, tools to increase equipment utilization will be established. All plants and all equipment are working together in one fully electronic “Data Acquisition and Management and Analysis System”. A major component during the elaboration of the new plant concept has been the evaluation of single use bioreactors (SUB). In a joint evaluation study of the sites in Basle and Penzberg, different SUB models were characterized up to a scale of 500 L and their suitability was examined in numerous fermentations. In order to ensure a compatibility of the single use bioreactors with the used media and cells, these tests were performed using our platform technologies for the development and production of antibodies. These platform processes require the realization of

    •Short mixing times

    •High mass transfer rates and

    •Sufficient power input.

    In the course of the evaluation, the best suitable SUBs were adapted in co-operation with the vendor to our requirements. Finally we ended up in a Roche-specific bioreactor design that guarantees comparable results to the existing stainless steel bioreactors. Apart from mechanical process engineering the adjustment of the automation systems plays a major role for the acceleration of the development process and increase of the flexibility. The development of an appropriate automation system covers several aspects:

    •Reliable and précised single use sensors are needed to operate SUBs in an efficient way.

    •The plant control system must integrate analytical devices, classic and single use bioreactors and harvest equipment using different control cabinets from different vendors.

    •The plant control and automation system has to integrate the operation of modular plants and research laboratories in different facilities.

    •Nevertheless, full remote control of all equipment and the use of advanced control algorithms must be feasible.

    •Interfaces of the data acquisition system have to support the use of many other different software tools used in R&D for process design and analysis.

    Having a complete electronic documentation & automation system available, we can use the advantages of our platform technologies to accelerate the development process.

    BibTeX:
    @standard{Eisenkraetzer2010,
      author = {Detlef Eisenkrätzer},
      title = {Implementation of new bioreactor & information technology into existing facilities},
      journal = {Roche Diagnostics GmbH (Germany)},
      year = {2010}
    }
    
    Paust, T. & Peuker, T. Disposables in biomanufacturing: Where we are – a manufacturer’s report 2010 Sartorius Stedim Biotech GmbH (Germany)  standard  
    Abstract:

    Patent expiries, competitive pressure, plant utilization, product safety, assurance of supply – just a few of all the buzz words that currently challenge the biopharmaceutical industry. The costs associated with the construction and operation of manufacturing capacities applied to clinical phases and large scale manufacturing require to challenge current manufacturing paradigms. Single-use technologies represent one of the options to look at in order to gain operational excellence. Having past its infant stage single-use technologies are increasingly used in biopharmaceutical manufacturing and are expected to grow substantially in the coming years. The full utilization of those advantages is mainly based on the ability of suppliers to provide the industry with adequate alternatives to existing, multiple-use scenarios. This presentation provides an overview about single-use technologies that are currently used in various up- and downstream manufacturing steps, highlighting a platform and unit operation based engineering approach that helps implement single-use technologies more efficiently. The consequences on modern facility designs will be discussed as well as the impact of cost models to the creation of a basis for decision on technologies to be applied.
    BibTeX:
    @standard{Paust2010,
      author = {Thomas Paust and Thorsten Peuker},
      title = {Disposables in biomanufacturing: Where we are – a manufacturer’s report},
      journal = {Sartorius Stedim Biotech GmbH (Germany)},
      year = {2010}
    }
    
    Pralong, A. Disposables in biomanufacturing: Where we are – a user’s report 2010 Crucell N.V. (Netherlands)  standard  
    Abstract:

    Traditional chemical engineering technology based on stainless steel has been applied as a standard in manufacturing of biopharmaceuticals over the last 30 years. Increasing requirements in quality and process control combined with relatively low product titers have led to highly complex and expensive equipment and facility layouts. The construction and commissioning of a new facility can take between 5 to 7 years and cost more than 350 million Euros. Since 15 years, significant efforts have been made to increase process productivity and to develop new manufacturing technologies permitting reduction of CAPEX and OPEX costs. Major developments of disposable technology during the last 10 years have resulted in the possibility to replace traditional stainless steel equipment. The combination of process productivity and new technologies has a significant impact on the strategy for development and manufacturing of biopharmaceuticals and the associated costs.
    BibTeX:
    @standard{Pralong2010,
      author = {Alain Pralong},
      title = {Disposables in biomanufacturing: Where we are – a user’s report},
      journal = {Crucell N.V. (Netherlands)},
      year = {2010}
    }
    

    Created by JabRef on 23/03/2010.